IMMUNOVANT INC (IMVT)
Health Care · biotechnology · NASDAQ
Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases.
What IMMUNOVANT INC does
Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Its primary product candidate is imeroprubart (IMVT-1402), a neonatal fragment crystallizable receptor (FcRn) inhibitor designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies. The company targets applications across several medical specialties including neurology, rheumatology, endocrinology, and dermatology.
Themes: autoimmune disease therapies, FcRn inhibitors, immunology drug development, IgG reduction therapies
Fundamentals
- Price$30.26 as of 2026-10-08 close
- Market cap$6.3B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+88.2% 2025-10-08 close $16.08 → 2026-10-08 close $30.26
- P/En/a negative earnings
- ROE-59.3% FY2026, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.20 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How IMVT compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How IMMUNOVANT INC looks technically
IMMUNOVANT INC (IMVT) is trading 4.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 229 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 18, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-05-19, breaking below its recent trading range. It is 33.4% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 4.8% below its 200-day average, the long-term trend line — a long-term downtrend | -4.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $38.58 | $38.58 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.78 | $31.78 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 229 trading days ago — a "golden cross", a bullish long-term signal | 229 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 27.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 18, in oversold territory (below 30) | 18.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($29.80 to $38.15) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 5.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.42 | $45.42 |
|---|---|---|
| From the 52-week high | it is 33.4% below its 52-week high (its highest price of the past year) | -33.4% |
| Above the 52-week low | it is 89.7% above its 52-week low (its lowest price of the past year) | +89.7% |
| Below the 52-week high | it is 33.4% below its highest point of the past year | 33.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-05-19, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-05-19, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $53.75 (set on 2020-11-18) | $53.75 |
| Given back of the 52-week move | over the past year its closes ranged ($16.07 to $44.96), and it has given back around half of its rise from last year’s low — 51% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.18 to $27.11. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 50.9% |
| From the all-time high | it is 43.7% below its all-time high | -43.7% |
| Nearest price level | it is sitting right on a support level at $30.19 — a price it turned at three times since 2026-04-23, most recently on 2026-06-03. Since 2024-10-08 it has 15 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $3.15 (set on 2022-06-13) | $3.15 |
| Above the all-time low | it is 862.2% above its all-time low | +862.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.46 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.46 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $30.41 and $39.05 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $30.41 – $34.73 – $39.05 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (4.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -2.0% |
|---|---|---|
| Open gap | it gapped 2.5% below the previous close 11 sessions ago and has not traded back through the level it left behind at 37.29 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.5% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 35 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 35 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 6 sessions in a row, a -10.42% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 6 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 24.6 percentage points (the stock lost 23.5% while the market gained 1.0%) | -24.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.8 percentage points (the stock lost 24.9% while the market gained 3.8%) | -28.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 4.1 percentage points (the stock gained 21.6% while the market gained 17.5%) | +4.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 73.3 percentage points (the stock gained 88.2% while the market gained 15.0%) | +73.3% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.7% of the share price. | -24.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $32.07 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -5.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $37.99 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -20.4% |
Price levels it has turned at before
IMVT last closed at $30.26 on 2026-10-08. Since 2024-10-08 it has turned at 15 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $30.19 | Support | 0.2% below the last close | turned there three times · 2026-04-23 to 2026-06-03 |
| $29.28 | Support | 3.2% below the last close | turned there three times · 2024-11-27 to 2026-02-25 |
| $28.27 | Support | 6.6% below the last close | turned there twice · 2024-10-16 to 2024-11-04 |
| $36.53 | Resistance | 20.7% above the last close | turned there twice · 2026-05-20 to 2026-08-03 |
| $41.22 | Resistance | 36.2% above the last close | turned there twice · 2026-07-09 to 2026-07-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · On a losing streak (5+ lower closes in a row) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$48.88 range $30.00 – $66.00; median $48.50
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMVT
- Consensus EPS estimate-$0.7221 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.7221, on 2026-09-04, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no commercial products, history of operating losses, and significant ongoing capital requirements.","Heavy reliance on the successful clinical development and regulatory approval of a single primary asset, IMVT-1402.","Dependence on third-party collaborations and potential risks associated with intellectual property licensing."]
What changed in the latest 10-Q
AI-assisted comparison of IMVT's 10-Q filed 2026-02-06 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-02-06) adds 'Immunovant, Inc.' in parentheses in Overview section opening: 'Immunovant, Inc. ("Immunovant," "we" or the "Company")' vs. older filing (2025-11-10) which states 'Immunovant is a clinical-stage immunology company'
- Removed:
- Older filing (2025-11-10) states 'across more than 20 indications currently being evaluated in clinical trials by multiple companies' - newer filing (2026-02-06) changes to 'across more than 20 indications that have been publicly announced for study by multiple companies'
- Reworded:
- Older filing (2025-11-10): 'have initiated and are currently enrolling studies in six indications' changed to newer filing (2026-02-06): 'have ongoing studies in six indications'
- Forward-Looking Statements section: older filing (2025-11-10) states 'Except as required by law' while newer filing (2026-02-06) states 'Except as required by applicable law'
- Notes:
- Both filings are truncated at the same point ('We initiated two potentia...' / 'We initiated two potentially registrational trial'), limiting full comparison of subsequent sections
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($223070) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 7 sells ($856180) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 35 sells ($13M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMVT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IMVT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 29,281,817
- Reported value $1,128,228,404
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IMVT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IMVT had 17,253,948 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IMVT had 8.35% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.34 days to cover at the same settlement.
- Reported short interest (shares) 17,253,948
- Short interest (% of shares outstanding) 8.35%
- Prior settlement (shares) 15,784,450
- Reported change 9.31%
- Days to cover (reported) 14.34
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Argenx (ARGX)
- Alexion Pharmaceuticals (AstraZeneca) (AZN)
- UCB (UCBJY)
- Johnson & Johnson (JNJ)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMVT vs…
Frequently asked questions
What does IMMUNOVANT INC (IMVT) do?
Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Its primary product candidate is imeroprubart (IMVT-1402), a neonatal fragment crystallizable receptor (FcRn) inhibitor designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies. The company targets applications across several medical specialties including neurology, rheumatology, endocrinology, and dermatology.
What sector is IMMUNOVANT INC (IMVT) in?
IMMUNOVANT INC (IMVT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are IMMUNOVANT INC's (IMVT) competitors?
Notable peers of IMMUNOVANT INC (IMVT) include Argenx, Alexion Pharmaceuticals (AstraZeneca), UCB, Johnson & Johnson and Amgen. This peer set is informational only — not financial advice.
Is IMMUNOVANT INC (IMVT) overbought or oversold right now?
IMMUNOVANT INC (IMVT) is currently in oversold territory (its 14-day RSI is 18, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMVT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.